{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:25:35Z","timestamp":1794302735309,"version":"4.9.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.eprac.2025.11.018","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:20:39Z","timestamp":1765988439000},"page":"623-635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2963-7259","authenticated-orcid":false,"given":"Naseem","family":"Eisa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Barood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2025.11.018_bib1","series-title":"IDF diabetes atlas","year":"2025"},{"key":"10.1016\/j.eprac.2025.11.018_bib2","series-title":"Obesity and overweight fact sheet","year":"2025"},{"issue":"9468","key":"10.1016\/j.eprac.2025.11.018_bib3","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.eprac.2025.11.018_bib4","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International diabetes Federation task force on epidemiology and prevention","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.eprac.2025.11.018_bib5","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Banting lecture 1988. Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.eprac.2025.11.018_bib6","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","article-title":"Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links","volume":"53","author":"DeFronzo","year":"2010","journal-title":"Diabetologia"},{"issue":"7121","key":"10.1016\/j.eprac.2025.11.018_bib7","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.eprac.2025.11.018_bib8","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1172\/JCI29069","article-title":"Inflammation and insulin resistance","volume":"116","author":"Shoelson","year":"2006","journal-title":"J Clin Invest"},{"issue":"7121","key":"10.1016\/j.eprac.2025.11.018_bib9","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nature05488","article-title":"Abdominal obesity and metabolic syndrome","volume":"444","author":"Despr\u00e9s","year":"2006","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.eprac.2025.11.018_bib10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/ATVBAHA.107.151092","article-title":"Metabolic syndrome pandemic","volume":"28","author":"Grundy","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"10.1016\/j.eprac.2025.11.018_bib11","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.eprac.2025.11.018_bib12","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"9548","key":"10.1016\/j.eprac.2025.11.018_bib13","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.eprac.2025.11.018_bib14","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2025.11.018_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2025.11.018_bib16","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2025.11.018_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2025.11.018_bib18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2025.11.018_bib19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"issue":"5","key":"10.1016\/j.eprac.2025.11.018_bib20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","article-title":"Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial","volume":"8","author":"Yabe","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2025.11.018_bib21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2025.11.018_bib22","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"10192","key":"10.1016\/j.eprac.2025.11.018_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.eprac.2025.11.018_bib24","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2025.11.018_bib25","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2025.11.018_bib26","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2025.11.018_bib27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","article-title":"Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, randomised, open-label, phase 3a trial","volume":"8","author":"Yamada","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"14","key":"10.1016\/j.eprac.2025.11.018_bib28","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.eprac.2025.11.018_bib29","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.eprac.2025.11.018_bib30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"10278","key":"10.1016\/j.eprac.2025.11.018_bib31","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.eprac.2025.11.018_bib32","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.eprac.2025.11.018_bib33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2025.11.018_bib34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"10.1016\/j.eprac.2025.11.018_bib35","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5","volume":"28","author":"Kushner","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"24","key":"10.1016\/j.eprac.2025.11.018_bib36","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2025.11.018_bib37","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1111\/dom.13331","article-title":"Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1\u20135 trials","volume":"20","author":"Warren","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2025.11.018_bib38","article-title":"Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity: exploratory analyses from the STEP 1, 2, and 3 trials","volume":"55","author":"Verma","year":"2023","journal-title":"Lancet EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.eprac.2025.11.018_bib39","first-page":"185","article-title":"Impact of semaglutide on high-sensitivity C-reactive protein in subjects with type 2 diabetes and\/or obesity","volume":"21","author":"Costa","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.eprac.2025.11.018_bib40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10157","key":"10.1016\/j.eprac.2025.11.018_bib41","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2025.11.018_bib42","article-title":"RoB 2: a revised tool for assessing risk of bias in randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.eprac.2025.11.018_bib43","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.11.018_bib44","article-title":"Semaglutide\u2019s immunomodulatory effects in patients with obesity: a pilot clinical study","volume":"7","author":"Gomez","year":"2025","journal-title":"Revista Arac\u00ea"},{"key":"10.1016\/j.eprac.2025.11.018_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1379189","article-title":"Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis","volume":"11","author":"Masson","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.eprac.2025.11.018_bib46","series-title":"Review manager (RevMan) [computer program]","year":"2020"},{"key":"10.1016\/j.eprac.2025.11.018_bib47","series-title":"R: A language and environment for statistical computing","year":"2023"},{"issue":"3","key":"10.1016\/j.eprac.2025.11.018_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1016\/j.eprac.2025.11.018_bib49","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2022"},{"issue":"10193","key":"10.1016\/j.eprac.2025.11.018_bib50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.eprac.2025.11.018_bib51","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.eprac.2025.11.018_bib52","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.eprac.2025.11.018_bib53","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2025.11.018_bib54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2025.11.018_bib55","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.eprac.2025.11.018_bib56","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.eprac.2025.11.018_bib57","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes (Lond)"},{"issue":"12","key":"10.1016\/j.eprac.2025.11.018_bib58","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.eprac.2025.11.018_bib59","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes (SOUL)","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.11.018_bib60","first-page":"174","article-title":"Efficacy and safety of once-weekly semaglutide versus once-weekly exenatide (SUSTAIN 3): a 56-week, open-label, randomised clinical trial","volume":"6","author":"Ahr\u00e9n","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2025.11.018_bib61","first-page":"1914","article-title":"Once-weekly semaglutide improves glycaemic control and reduces body weight in adults with type 2 diabetes: SUSTAIN 2 trial","volume":"20","author":"Ludvik","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.eprac.2025.11.018_bib62","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2025.11.018_bib63","article-title":"GLP-1 receptor agonists and weight loss: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Tchang","year":"2023","journal-title":"Obes Rev"},{"issue":"11","key":"10.1016\/j.eprac.2025.11.018_bib64","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jamainternmed.2024.4346","article-title":"Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5 trials","volume":"184","author":"Wadden","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.11.018_bib65","article-title":"Effect of semaglutide on apnea-hypopnea index in adults with obesity and obstructive sleep apnea: randomized controlled trial","volume":"48","author":"Smith","year":"2025","journal-title":"Sleep"},{"key":"10.1016\/j.eprac.2025.11.018_bib66","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes: a phase 3b, double-blind, randomised, placebo-controlled trial (STRIDE)","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.eprac.2025.11.018_bib67","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.11.018_bib68","first-page":"123","article-title":"GLP-1 receptor agonists and cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Nunes","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.eprac.2025.11.018_bib69","series-title":"FDA drug safety communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes","year":"2013"},{"issue":"6","key":"10.1016\/j.eprac.2025.11.018_bib70","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2025.11.018_bib71","first-page":"1703","article-title":"Development of IWQOL-lite for clinical trials: results from two studies","volume":"22","author":"Bjorner","year":"2014","journal-title":"Obesity (Silver Spring)"},{"issue":"24","key":"10.1016\/j.eprac.2025.11.018_bib72","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.11.018_bib73","first-page":"1","article-title":"Tirzepatide and semaglutide for the treatment of obstructive sleep apnea and obesity","volume":"13","author":"Baser","year":"2025","journal-title":"Med Res Arch"},{"key":"10.1016\/j.eprac.2025.11.018_bib74","first-page":"1234","article-title":"Muscle preservation during weight loss with semaglutide: the COURAGE trial","volume":"33","author":"Tchang","year":"2025","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"10.1016\/j.eprac.2025.11.018_bib75","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eprac.2025.11.018_bib76","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10295","key":"10.1016\/j.eprac.2025.11.018_bib77","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2025.11.018_bib78","first-page":"156","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP UP randomized clinical trial","volume":"333","author":"Wadden","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.eprac.2025.11.018_bib79","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2337\/dc24-2425","article-title":"High-dose semaglutide (up to 16 mg) in people with type 2 diabetes and overweight or obesity","volume":"48","author":"Davies","year":"2025","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.eprac.2025.11.018_bib80","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.eprac.2025.11.018_bib81","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"10103","key":"10.1016\/j.eprac.2025.11.018_bib82","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eprac.2025.11.018_bib83","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41588-021-00857-4","article-title":"Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology","volume":"53","author":"Mullins","year":"2021","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.eprac.2025.11.018_bib84","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1212\/01.wnl.0000244749.20056.d4","article-title":"Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study","volume":"68","author":"Edison","year":"2007","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.eprac.2025.11.018_bib85","first-page":"2874","article-title":"The role of alpha-linolenic acid in cancer prevention","volume":"19","author":"Ligumsky","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.eprac.2025.11.018_bib86","first-page":"789","article-title":"Subcutaneous semaglutide 2.4 mg for the treatment of non-alcoholic steatohepatitis: the ESSENCE trial","volume":"405","author":"Newsome","year":"2025","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2025.11.018_bib87","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.11.018_bib88","first-page":"121","article-title":"The role of TNF-alpha in the pathogenesis of psoriasis and the effect of anti-TNF-alpha treatment","volume":"20","author":"Faurschou","year":"2007","journal-title":"Skin Pharmacol Physiol"},{"issue":"22","key":"10.1016\/j.eprac.2025.11.018_bib89","first-page":"2001","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"Husain","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2025.11.018_bib90","first-page":"1456","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"392","author":"Frias","year":"2025","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.eprac.2025.11.018_bib91","first-page":"1789","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2501331X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2501331X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:16:33Z","timestamp":1776467793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2501331X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":91,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1530891X2501331X"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.11.018","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}